




Searching News Database: Agendia
HSMN NewsFeed - 11 Sep 2019
Immunexpress Appoints Jane Papadaki Markley as VP of Market Development and Commercial Operations
Immunexpress Appoints Jane Papadaki Markley as VP of Market Development and Commercial Operations
HSMN NewsFeed - 18 Sep 2018
Agendia and Genecast Biotechnology Partner to Launch MammaPrint(R) and BluePrint(R) in China
Agendia and Genecast Biotechnology Partner to Launch MammaPrint(R) and BluePrint(R) in China
HSMN NewsFeed - 19 Dec 2017
Agendia and Bluebee Partner to Bring New NGS-based MammaPrint(R) BluePrint(R) Breast Cancer Kit to Market
Agendia and Bluebee Partner to Bring New NGS-based MammaPrint(R) BluePrint(R) Breast Cancer Kit to Market
HSMN NewsFeed - 17 Feb 2014
Published Study Validates Agendia’s MammaPrint Test for Long-Term Prediction of Breast Cancer Outcome
Published Study Validates Agendia’s MammaPrint Test for Long-Term Prediction of Breast Cancer Outcome
HSMN NewsFeed - 9 Jul 2012
Agendia Names Industry Veteran Glen Fredenberg CFO and Vice President of Finance
Agendia Names Industry Veteran Glen Fredenberg CFO and Vice President of Finance
HSMN NewsFeed - 1 Jun 2012
Agendia Announces Launch of ColoPrint for Colon Cancer Prognosis and Prediction
Agendia Announces Launch of ColoPrint for Colon Cancer Prognosis and Prediction
HSMN NewsFeed - 6 Dec 2011
Agendia Introduces the SYMPHONY(TM) Breast Cancer Profile With Paraffin Embedded Tissue
Agendia Introduces the SYMPHONY(TM) Breast Cancer Profile With Paraffin Embedded Tissue
HSMN NewsFeed - 18 Feb 2009
Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
HSMN NewsFeed - 4 Feb 2009
Agendia's Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
Agendia's Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
HSMN NewsFeed - 12 Dec 2008
Agendia's MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
Agendia's MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
HSMN NewsFeed - 3 Oct 2007
Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
HSMN NewsFeed - 6 Feb 2007
Agendia Receives U.S. FDA Clearance for MammaPrint Breast Cancer Diagnostic Test
Agendia Receives U.S. FDA Clearance for MammaPrint Breast Cancer Diagnostic Test
Additional items found! 5

Members Archive contains
5 additional stories matching:
Agendia
(Password required)
Agendia
(Password required)